Louis M Weiner

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Monoclonal antibody therapy of cancer
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Nat Biotechnol 23:1147-57. 2005
  2. ncbi request reprint Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer
    Louis M Weiner
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19, 111, USA
    Nat Rev Cancer 7:701-6. 2007
  3. ncbi request reprint Fully human therapeutic monoclonal antibodies
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Immunother 29:1-9. 2006
  4. ncbi request reprint Targeted therapies in solid tumors: monoclonal antibodies and small molecules
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Hum Antibodies 15:103-11. 2006
  5. ncbi request reprint Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen
    Yong Tang
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Immunol 179:2815-23. 2007
  6. doi request reprint Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
  7. pmc Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Jiping Zhang
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    FASEB J 27:581-9. 2013
  8. pmc Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
    Igor A Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 34:70-5. 2011
  9. pmc Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
    Stephen I Rudnick
    Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Cancer Res 71:2250-9. 2011
  10. ncbi request reprint Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Monoclonal antibody therapy of cancer
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Nat Biotechnol 23:1147-57. 2005
    ..Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting...
  2. ncbi request reprint Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer
    Louis M Weiner
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19, 111, USA
    Nat Rev Cancer 7:701-6. 2007
    ..These advances will be complemented by the use of antibodies that induce clinically meaningful host-protective immune responses. But, can we afford this progress?..
  3. ncbi request reprint Fully human therapeutic monoclonal antibodies
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Immunother 29:1-9. 2006
    ..In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues...
  4. ncbi request reprint Targeted therapies in solid tumors: monoclonal antibodies and small molecules
    Louis M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Hum Antibodies 15:103-11. 2006
    ....
  5. ncbi request reprint Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen
    Yong Tang
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Immunol 179:2815-23. 2007
    ..Because high affinity may impair in vivo tumor targeting, a careful examination of Ab structure to function relationships is required to develop optimized therapeutic unconjugated Abs...
  6. doi request reprint Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
    ....
  7. pmc Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Jiping Zhang
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    FASEB J 27:581-9. 2013
    ..15% (mutant E3), respectively. Thus, we have identified and affinity-maturated the first scFv antibody capable of inhibiting FAP function. This scFv antibody has the potential to disrupt the role of FAP in tumor invasion and metastasis...
  8. pmc Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
    Igor A Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 34:70-5. 2011
    ..We evaluated the role of the anti-vascular endothelial growth factor antibody bevacizumab as second-line treatment for patients with metastatic pancreatic cancer...
  9. pmc Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
    Stephen I Rudnick
    Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Cancer Res 71:2250-9. 2011
    ..Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors...
  10. ncbi request reprint Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
    ..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
  11. ncbi request reprint Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Mol Cancer Ther 4:351-60. 2005
    ....
  12. ncbi request reprint Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 12:1599-605. 2006
    ..25 %ID/g). These findings substantiate that the improved tumor retention of (sFv')2 homodimers over sFv monomers results from the availability of dual binding sites rather than from the slower systemic clearance of homodimers...
  13. ncbi request reprint Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
    ....
  14. ncbi request reprint Isolation of scFvs to in vitro produced extracellular domains of EGFR family members
    Eva Horak
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Biother Radiopharm 20:603-13. 2005
    ..These scFvs provide a valuable and potentially clinically relevant panel of agents to target the members of the EGFR family...
  15. pmc A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
    Crystal S Denlinger
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA Electronic address
    Clin Colorectal Cancer 13:81-6. 2014
    ..Preclinical data suggest that proteasome inhibition may be an effective therapeutic strategy. We thus evaluated the clinical efficacy of bortezomib in advanced biliary tract cancers...
  16. ncbi request reprint Monoclonal antibodies in therapy of solid tumors
    David M Heimann
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Surg Oncol Clin N Am 16:775-92, viii. 2007
    ..Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trials...
  17. pmc Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
    Liat Binyamin
    Department of Medical Oncology and Division of Basic Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol 180:6392-401. 2008
    ..This method provides an alternative approach to potentiate the therapeutic benefit of antitumor Abs that mediate ADCC...
  18. ncbi request reprint Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
    Lillian S Shahied
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Biol Chem 279:53907-14. 2004
    ..Both minibody constructs are stable in mouse and human serum for up to 72 h at 37 degrees C. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes...
  19. doi request reprint Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 31:1-5. 2008
    ..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...
  20. pmc Mechanisms of tumor resistance to EGFR-targeted therapies
    Elizabeth A Hopper-Borge
    Fox Chase Cancer Center, W462, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Expert Opin Ther Targets 13:339-62. 2009
    ..Many cancers are either initially resistant to EGFR inhibitors or become resistant during treatment, limiting the efficacy of these reagents...
  21. ncbi request reprint Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
    ....
  22. pmc Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation
    Anna Sukhanova
    Program in Developmental Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Discov 3:96-111. 2013
    ..Analysis of Nsdhl-deficient Bpa(1H/+) mice confirmed dramatic and selective loss of internalized platelet-derived growth factor receptor in fibroblasts, and reduced activation of EGFR and its effectors in regions of skin lacking NSDHL...
  23. ncbi request reprint Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer
    Lorraine C Snyder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2412, USA
    Clin Colorectal Cancer 5:S71-80. 2005
    ..The presence of skin rash and EGFR gene amplification have been advanced as possible predictors of clinical effectiveness of targeted anti-EGFR therapies...
  24. ncbi request reprint Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:4767-72. 2002
    ..Moreover, tumor growth is attenuated by antibodies that inhibit the proteolytic activity of FAP. These findings suggest a possible therapeutic role for functional inhibition of FAP activity...
  25. ncbi request reprint Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report
    Melvyn Goldberg
    Fox Chase Cancer Center, Division of Thoracic Surgical Oncology, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Thorac Cardiovasc Surg 126:1168-73. 2003
    ..To assess the benefits of aggressive chemoradiation therapy followed by surgery in resectable esophageal carcinoma...
  26. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
    ..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
  27. ncbi request reprint Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 53:513-8. 2004
    ....
  28. pmc Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer
    Natalya Beglyarova
    Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Clin Cancer Res . 2016
    ..Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies optimally targeting the tumors of individual patients...
  29. ncbi request reprint A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice
    Gregory P Adams
    Divison of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 64:6200-6. 2004
    ..The maximum tolerated dose was also dependent on the tumor xenograft model used. These studies indicate that genetically engineered antitumor diabody molecules can be used as effective vehicles for radioimmunotherapy...
  30. ncbi request reprint Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 6:125-32. 2006
    ....
  31. pmc Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies
    Margaret von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
    Cancer Chemother Pharmacol 75:1047-55. 2015
    ..Combination therapy with trabectedin and docetaxel was evaluated in patients with advanced malignancies...
  32. pmc Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 69:358-63. 2007
    ....
  33. pmc Synthetic lethal screen of an EGFR-centered network to improve targeted therapies
    Igor Astsaturov
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Sci Signal 3:ra67. 2010
    ..Such a focused approach can potentially improve the coherent design of combination cancer therapies...
  34. ncbi request reprint Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 22:602-9. 2004
    ..PNU-214936 is a murine Fab fragment of the monoclonal antibody 5T4 fused to a mutated superantigen staphylococcal enterotoxin A (SEA)...
  35. ncbi request reprint Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647
    Jonathan D Cheng
    Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 9:1590-5. 2003
  36. ncbi request reprint Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development
    Sandra Urtishak
    Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Biomark Med 2:137-45. 2008
    ..Therefore, CTC and CEC enumeration and analysis represent a clinically meaningful tool for assessing prognosis, monitoring response to therapy, pharmacodynamic studies and rational selection of therapies in cancer patients...
  37. ncbi request reprint Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 13:214-20. 2006
    ..On the basis of encouraging data from a phase I trial, we conducted a phase II study of preoperative chemotherapy, followed by concurrent chemoradiotherapy and surgery...
  38. ncbi request reprint Monoclonal antibody therapy for cancer
    Margaret von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
    Annu Rev Med 54:343-69. 2003
    ..Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors...
  39. ncbi request reprint Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control cancer
    Louis M Weiner
    Department of Medical Oncology Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 16:7-9. 2002
  40. ncbi request reprint The rollercoaster ride to anti-cancer antibodies
    Louis M Weiner
    Nat Biotechnol 21:510-1. 2003
  41. ncbi request reprint Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer
    Benjamin Movsas
    Henry Ford Health System, Radiation Oncology, Detroit, MI 48202, USA
    Am J Clin Oncol 29:435-41. 2006
    ..The purpose of this phase II study was to prospectively determine the efficacy of preoperative chemoradiation with a hyperfractionated (Hfx) RT boost to 61.8 Gy in locally advanced rectal cancer...
  42. ncbi request reprint Global gene expression profiling of circulating tumor cells
    Denis A Smirnov
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Cancer Res 65:4993-7. 2005
    ..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...
  43. doi request reprint Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
    Louis M Weiner
    Georgetown University Medical Center, Washington, DC 20057 1465, USA
    Clin Cancer Res 14:502-8. 2008
    ....
  44. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  45. ncbi request reprint Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors
    Robert A Beckman
    Clinical Hematology Oncology, Centocor Research and Development, Inc, Malvern, Pennsylvania 19355, USA
    Cancer 109:170-9. 2007
    ..These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors...
  46. ncbi request reprint Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Immunother 30:577-90. 2007
    ....
  47. ncbi request reprint Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
    Howard L Kaufman
    Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA
    J Clin Oncol 22:2122-32. 2004
    ..The induction of PSA-specific immunity was also evaluated...
  48. ncbi request reprint Tunable antibodies
    Louis M Weiner
    Nat Biotechnol 23:556-7. 2005
  49. doi request reprint Translational Research Working Group developmental pathway for immune response modifiers
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 14:5692-9. 2008
    ..This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway...
  50. doi request reprint From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics
    Louis M Weiner
    Cancer J 14:147-8. 2008
  51. ncbi request reprint A review of antibody therapeutics and antibody-related technologies for oncology
    Bernard J Scallon
    Centocor, Malvern, PA 19355, USA
    J Immunother 29:351-64. 2006
  52. pmc Cancer immunotherapy--the endgame begins
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    N Engl J Med 358:2664-5. 2008